1
|
Zhang P, Shi C, Dong T, Song J, Du G. The anticancer therapeutic potential of pyrimidine-sulfonamide hybrids. Future Med Chem 2024; 16:905-924. [PMID: 38624011 PMCID: PMC11249161 DOI: 10.4155/fmc-2024-0010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 03/27/2024] [Indexed: 04/17/2024] Open
Abstract
Cancer as a devastating malignancy, seriously threatens human life and health, but most chemotherapeutics have long been criticized for unsatisfactory therapeutic efficacy due to drug resistance and severe off-target toxicity. Pyrimidines, including fused pyrimidines, are privileged scaffolds for various biological cancer targets and are the most important class of metalloenzyme carbonic anhydrase inhibitors. Pyrimidine-sulfonamide hybrids can act on different targets in cancer cells simultaneously and possess potent activity against various cancers, revealing that hybridization of pyrimidine with sulfonamide is a promising approach to generate novel effective anticancer candidates. This review aims to summarize the recent progress of pyrimidine-sulfonamide hybrids with anticancer potential, covering papers published from 2020 to present, to facilitate further rational design of more effective candidates.
Collapse
Affiliation(s)
- Peng Zhang
- Emergency Intensive Care Medicine Department, Zibo 148 Hospital, China RongTong Medical Healthcare Group Co. Ltd, Zibo, Shandong Province, 255000, PR China
| | - Congcong Shi
- Zibo Vocational Institute College of Medical Technology, Zibo, Shandong Province, 255000, PR China
| | - Tongbao Dong
- Zibo Vocational Institute College of Medical Technology, Zibo, Shandong Province, 255000, PR China
| | - Juntao Song
- Hematology & Oncology Department, Zibo 148 Hospital, China RongTong Medical Healthcare Group Co. Ltd, Zibo, Shandong Province, 255000, PR China
| | - Gang Du
- Emergency Intensive Care Medicine Department, Zibo 148 Hospital, China RongTong Medical Healthcare Group Co. Ltd, Zibo, Shandong Province, 255000, PR China
| |
Collapse
|
2
|
Xue Y, Mu S, Sun P, Sun Y, Liu N, Sun Y, Wang L, Zhao D, Cheng M. Design, synthesis, and biological evaluation of novel pyrimidin-2-amine derivatives as potent PLK4 inhibitors. RSC Med Chem 2023; 14:1787-1802. [PMID: 37731702 PMCID: PMC10507801 DOI: 10.1039/d3md00267e] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Accepted: 07/12/2023] [Indexed: 09/22/2023] Open
Abstract
Serine/threonine protein kinase PLK4 is a master regulator of centriole duplication, which is significant for maintaining genome integrity. Accordingly, due to the detection of PLK4 overexpression in a variety of cancers, PLK4 has been identified as a candidate anticancer target. Thus, it is a very meaningful to find effective and safe PLK4 inhibitors for the treatment of cancer. However, the reported PLK4 inhibitors are scarce and have potential safety issues. In this study, a series of novel and potent PLK4 inhibitors with an aminopyrimidine core was obtained utilizing the scaffold hopping strategy. The in vitro enzyme activity results showed that compound 8h (PLK4 IC50 = 0.0067 μM) displayed high PLK4 inhibitory activity. In addition, compound 8h exhibited a good plasma stability (t1/2 > 289.1 min), liver microsomal stability (t1/2 > 145 min), and low risk of DDIs. At the cellular level, it presented excellent antiproliferative activity against breast cancer cells. Taken together, these results suggest that compound 8h has potential value in the further research of PLK4-targeted anticancer drugs.
Collapse
Affiliation(s)
- Yanli Xue
- Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District 110016 Shenyang China
| | - Shuyi Mu
- Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District 110016 Shenyang China
| | - Pengkun Sun
- Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District 110016 Shenyang China
| | - Yin Sun
- Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District 110016 Shenyang China
| | - Nian Liu
- Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District 110016 Shenyang China
| | - Yu Sun
- Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District 110016 Shenyang China
| | - Lin Wang
- Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District 110016 Shenyang China
| | - Dongmei Zhao
- Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District 110016 Shenyang China
| | - Maosheng Cheng
- Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University 103 Wenhua Road, Shenhe District 110016 Shenyang China
| |
Collapse
|
3
|
Development of Pyrimidine- Cinnamamide Hybrids as Potential Anticancer agents: A Rational Design Approach. J Mol Struct 2022. [DOI: 10.1016/j.molstruc.2022.133594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
4
|
Guo M, Wang H, Yang J, Wang X, Zhang J, Liu S, Wei S, Jiang N, Zhai X. Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. Eur J Med Chem 2022; 238:114493. [DOI: 10.1016/j.ejmech.2022.114493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 05/13/2022] [Accepted: 05/23/2022] [Indexed: 11/04/2022]
|
5
|
Ding L, Zhang Q, Zhao K, Jiao X, Zhou Y, Fan W, Tang C. Synthesis and biological evaluation of novel 5,6-dihydrobenzo[h]quinazoline derivatives as FLT3 inhibitors. Chem Biol Drug Des 2021; 99:527-534. [PMID: 34877799 DOI: 10.1111/cbdd.13992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Revised: 11/10/2021] [Accepted: 11/27/2021] [Indexed: 11/29/2022]
Abstract
Fms-like tyrosine kinase 3 (FLT3) is widely expressed and often mutated in acute myeloid leukemia (AML), which makes it an important target for the treatment of AML. The structure-based synthesis and biological evaluation of 5,6-dihydrobenzo[h]quinazoline derivatives as FLT3 inhibitors have been studied in this paper. III-1a, III-1c, III-2a, III-2c, and III-4a displayed comparable inhibitory potency against FLT3-ITD and showed remarkable antiproliferative activities against MV4-11.
Collapse
Affiliation(s)
- Lei Ding
- School of Pharmaceutical Science, Jiangnan University, Wuxi, China
| | - Qing Zhang
- School of Pharmaceutical Science, Jiangnan University, Wuxi, China
| | - Kuantao Zhao
- School of Pharmaceutical Science, Jiangnan University, Wuxi, China
| | - Xiaoyu Jiao
- School of Pharmaceutical Science, Jiangnan University, Wuxi, China
| | - Ying Zhou
- School of Pharmaceutical Science, Jiangnan University, Wuxi, China
| | - Weizheng Fan
- School of Pharmaceutical Science, Jiangnan University, Wuxi, China
| | - Chunlei Tang
- School of Pharmaceutical Science, Jiangnan University, Wuxi, China
| |
Collapse
|